Last Update: Jun 18, 2026
A Randomized, Double Masked, Placebo-controlled, Multicenter, Dose-range Finding Study to Assess the Efficacy and Safety of FWY003 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
ClinicalTrials.gov Identifier:
Novartis Reference Number:CFWY003A12201
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This study is designed as a randomized, multi-center, double-masked, prospective study to characterize the dose response relationship, efficacy and safety of FWY003.

Geographic Atrophy Secondary to Age-related Macular Degeneration
Phase2
Recruiting
272
Mar 09, 2026
Aug 22, 2029
All
50 Years - (Adult, Older Adult)

Interventions

Drug

FWY003

FWY003 arm participants will receive a specific dose of FWY003
Drug

Placebo

Placebo arm participants will receive placebo

Eligibility Criteria

Inclusion Criteria:

Male or female participants ≥ 50 years of age.

* A diagnosis of GA secondary to AMD in at least one eye (study eye). If both eyes qualify, then the eye with the better BCVA would be assigned as study eye.

1. Total GA area must be ≥2.5 and ≤17.5 mm2 (1 and 7 disk areas (DA), respectively)
2. If GA lesion is multifocal, then the total lesion area must be between 2.5-17.5 mm2 and at least one lesion should have an area of at least 1.25 mm2
3. Entire GA lesion must be visualized on the macula centered image and not contiguous with peripapillary atrophy
* ETDRS BCVA ≥ 35 letters (20/200) in the study eye.

Exclusion Criteria:

* A history of, or current evidence of, choroidal neovascularization (exudative MNV) in either eye, as determined by the central reading center on multimodal imaging at screening.
* Previous cell or gene therapy in either eye.
* Macular atrophy in either eye due to a cause other than AMD, such as Stargardt disease, cone rod dystrophy, toxic maculopathies, etc.
* Intraocular surgery, including cataract and vitreoretinal surgery, in the study eye within 3 months prior to Baseline.
* Presence of significant media opacity, eye movement disorder (nystagmus), severe ptosis, extraocular motility restriction or head tremor, which in the opinion of the investigator, would prevent adequate fundus visualization or interfere with retinal imaging data quality.

Other protocol-defined inclusion/exclusion criteria may apply.

Novartis Investigative Site

Recruiting

Parramatta,New South Wales,2150,Australia

Novartis Investigative Site

Recruiting

Albury,New South Wales,2640,Australia

Novartis Investigative Site

Recruiting

East Melbourne,Victoria,3002,Australia

Novartis Investigative Site

Recruiting

Strathfield,New South Wales,2135,Australia

Novartis Investigative Site

Recruiting

Sofia,1618,Bulgaria

Novartis Investigative Site

Recruiting

Ottawa,Ontario,K2b 7e9,Canada

Novartis Investigative Site

Recruiting

Prague,100 34,Czechia

Novartis Investigative Site

Recruiting

Prague,128 08,Czechia

Novartis Investigative Site

Recruiting

Paris,75940,France

Novartis Investigative Site

Recruiting

Lyon,Rhone,69004,France

Novartis Investigative Site

Recruiting

Créteil,94000,France

Novartis Investigative Site

Recruiting

Tübingen,72076,Germany

Novartis Investigative Site

Recruiting

Bonn,53105,Germany

Novartis Investigative Site

Recruiting

Pécs,Baranya,7621,Hungary

Novartis Investigative Site

Recruiting

Roma,RM,00184,Italy

Novartis Investigative Site

Recruiting

Milan,MI,20132,Italy

Novartis Investigative Site

Recruiting

Krakow,31-070,Poland

Novartis Investigative Site

Recruiting

Bydgoszcz,Kuyavian-Pomeranian Voivodeship,85 631,Poland

Novartis Investigative Site

Recruiting

Bucharest,011658,Romania

Novartis Investigative Site

Recruiting

Cluj-Napoca,Cluj,400006,Romania

Novartis Investigative Site

Recruiting

Burjassot,Valencia,46100,Spain

Erie Retina Research LLC

Recruiting

Erie,Pennsylvania,16505,United States

Jade Horn
David Almeida

New York Eye and Ear Infirmary of Mount Sinai

Recruiting

New York,New York,10003,United States

Katy Tai
Richard Rosen

Columbia University Medical Center

Recruiting

New York,New York,10032,United States

Sokleab Em
Tongalp Tezel

California Retina Consultants

Recruiting

Santa Barbara,California,93103,United States

Muskaan Kaur Bal
Dante Pieramici

NJ Retina

Recruiting

Toms River,New Jersey,08755,United States

Howard Fine
Andy Merino

Salehi Retina Institute

Recruiting

Huntington Beach,California,92647,United States

Hani Salehi-Had
Gillian Nguyen

Advanced Research LLC

Recruiting

Boynton Beach,Florida,33437,United States

Alayka Reddy
Drew Philip Bawcombe

Advanced Research LLC

Recruiting

Deerfield Beach,Florida,33064,United States

Isabella Villalonga
Shailesh Gupta

Opthamalic Consultants of Boston

Recruiting

Boston,Massachusetts,02114,United States

Hanna Raymond
Jeffrey S Heier

Retina Vitreous Associates of Florida

Recruiting

St. Petersburg,Florida,33711,United States

David Eichenbaum
Logan Wilson

Retina Consultants TX Rsrch Ctr

Recruiting

Bellaire,Texas,77401,United States

MaryGrace Powers
David M Brown

Retina Consultants of Texas

Recruiting

Katy,Texas,77494,United States

Kenneth Fan
Kymmia Majedi

Retinal Consultants Medical Group Inc

Recruiting

Sacramento,California,95841,United States

Daniel Ortiz
Margaret Chang

Retina Consultants of Houston PA

Recruiting

Houston,Texas,77030,United States

Charles C Wykoff
Erin Shelato

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Novartis Pharmaceuticals